Aurion Biotech

Aurion Biotech, founded in 2022, is a promising clinical-stage biotech company, headquartered in the United States, with a clear mission embodied in its slogan: "We're on a mission to cure blindness with our transformational platform of advanced therapies."

Specializing in biopharma and biotechnology, the company is actively developing pioneering solutions in health care. With its first candidate targeting corneal endothelial disease, Aurion Biotech is spearheading one of the first clinically validated cell therapies dedicated to corneal care.

The company secured a substantial $120.00M in a Venture Round investment on 12 April 2022. This illustrates robust investor confidence backed by leading names like Falcon Vision, Flying L Partners, Visionary Ventures, Alcon, Petrichor Healthcare Capital Management, and Deerfield. With its focus on a high-impact area, Aurion Biotech presents a compelling opportunity for investors in advanced medical therapies.